高坤,孙进,何仲贵
GAO Kun;SUN Jin;HE Zhong-gui(School of Pharmacy;

• 1:沈阳药科大学药学院
• 2:沈阳药科大学药学院
• 3:沈阳药科大学药学院 辽宁沈阳110016
• 4:辽宁沈阳110016

摘要(Abstract)：

目的对Caco 2细胞模型在口服药物肠吸收研究中的应用作一综述。方法在引用了自1974~2004年的32篇文献的基础上,通过介绍并比较体外Caco 2模型和体内药物吸收转运的不同途径,讨论Caco 2单层细胞模型在预测不同类药物体内吸收中的作用。结果Caco 2细胞模型可以预测不同转运途径的药物体内吸收,尤其适用于被动转运药物,这一细胞模型在药物吸收机制、处方组成透膜性和黏膜毒性、药物吸收过程中的相互作用、药物的化学结构和体内转运关系、药物吸收限速因素、药物代谢稳定性及pH对药物吸收的影响等研究中均有较广泛的应用。结论Caco2细胞模型用于预测各种途径的药物吸收,在细胞水平上提供了大量与吸收相关的信息,是口服药物高通量筛选的良好工具。
Objective To review the important applications of Caco2 cell monolayers in the study of the intestinal absorption of oral drug.Methods Based on 32 papers published from 1974 to 2004,the different routes of drug transport in Caco2 cell monolayers are compared with those seen in vivo and the prediction of drug absorption in vivo from transport experiments in cell monolayers is discussed for different classes of drug.Results Caco2 cell monolayers model could predict the absorption of drugs transported by different routes,especially for the passive transport drugs,this cell model was applied extensively in the study of the mechanism of absorption,permeability and toxity to mucous membrane of drug formulation component,interactions between drugs in the process of absorption,relationship between the chemical structures and transport in vivo,restricted step of absorption,metabolism of drugs and the effect of pH on the absorption.Conclusions(Caco2) cell monolayers model can predict the absorption of drugs transported by different routes and provide a large amount of information related to the drug absorption.It can be used as effective tool for oral drug high-throughput screening.

关键词(KeyWords)： 药物转运;药物吸收;Caco-2;单细胞层
drug transport;drug absorption;Caco2;cell monolayers

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(30400563)

作者(Authors): 高坤,孙进,何仲贵
GAO Kun;SUN Jin;HE Zhong-gui(School of Pharmacy;

参考文献(References)：

• [1]杨海涛,王广基.Caco 2单层细胞模型及其在药学中的应用[J].药学学报,2000,35(10):797-800.
• [2]Pappenheimer J R,Reiss K Z.Contribution of solventdrag through intercellular junctions to absorption ofnutrients by the small intestine of the rat[J].J MembrBio,1987,100(2):123-136.
• [3]Nellan H N.Paracellular intestinal transport:modula-tion of absorption[J].Adv Drug Deliv Rev,1991,7(3):339-364.
• [4]Furuse M,Hirase T,Itoh M,et al.Occludin:a novelintegral membrane protein localizing at tight junction[J].J Cell Bio,1993,123(6 Pt 2):1777-1788.
• [5]Lennernas H,Nilsson D,Aquilonius S M,et al.The ef-fect ofL-leucin on the absorption of levodopa,studiedby regional jejeunal perfusion in man[J].Br J ClinPharmacol,1993,35(3):243-250.
• [6]Phung-Ba V,Warnery A,Scherman D,et al.Interac-tion of pristinamycin IA with P glycoprotein in humanintestinal epithelial cells[J].Eur J Pharmacol,1995,288(2):187-192.
• [7]Hunter J,Jepson M A,Tsuruo T,et al.Functional ex-pression of P-glycoprotein in apical membranes of hu-man intestinal Caco 2 cells[J].J Biol Chem,1993,268(20):14991-14997.
• [8]de Aizpurua H J,Russel Jones G J.Oral vaccination.I-dentification of classes of proteins that provoke an im-mune response upon oral feeding[J].J Exp Med,1988,167(2):440-451.
• [9]Artursson P,Karlsson J.Correlation between oral drugabsorption in humans and apparent drug permeabilitycoefficients in human intestinal epithelial(Caco 2)cells[J].Biochem Biophys Res Commun,1991,175(3):880-885.
• [10]Wils P,Warnery A,Phung-Ba V,et al.Differentiatedintestinal epithelial cell lines asin vitromodels for pre-dicting the intestinal absorption of drugs[J].Cell BiolToxicol,1994,10(5-6):393-397.
• [11]Lennernas H,Palm K,Fagerholm U,et al.Comparisonbetween active and passive drug transport in human in-testinal epithelial(Caco 2)cellsin vitroand humanjejunumin vivo[J].Int J Pharm,1996,127(1):103-107.
• [12]Wilson F A,Dietschy I M.The intestinal unstirred wa-ter layer:its surface area and effect on active transportkinetics[J].Biochim Biophys Acta,1974,363(1):112-126.
• [13]Artursson P,Ungell A L,Lofroth J E.Selective para-cellualr permeability in two models of intestinal absorp-tion:cultured monolayers of human intestinal epithelialcells and rat intestinal segments[J].Pharm Res,1993,10(8):1123-1129.
• [14]Ma T Y,Hollander D,Bhalla D,et al.IEC 18,a non-transformed small intestinal cell line for studying ep-ithelial permeability[J].J Lab Clin Med,1992,120(2):329-341.
• [15]Wikman-Larhed A,Artursson P.Co-cultures of humanintestinal goblet(HT29 H)absorption(Caco 2)cellsfor studies of drug and peptide absorption[J].Eur JPharm Sci,1995,3(3):171-183.
• [16]Hidalgo I J,Borchardt R T.Transport of a large neu-tral amino acid(phenylalanine)in a human intestinalepithelial cell line:Caco 2[J].Biochim Biophys Acta,1990,1028(1):25-30.
• [17]Stewart B H,Chan O H,Lu R H,et al.Comparison ofintestinal permeabilities determined in multiplein vit-roand in situ models:Relationship to absorption in hu-mans[J].Pharm Res,1995,12(5):693-699.
• [18]Walter E,Kissel T.Heterogeneity in the human in-testinal cell line Caco 2 leads to differences in transep-ithelial transport[J].Eur J Pharm Sci,1995,3(4):215-230.
• [19]Nicklin P,Irwin B,Hassan I,et al.Permeable supporttype influences the transport of compounds acrossCaco 2 cells[J].Int J Pharm,1992,83(1-3):197-209.
• [20]Jumarie C,Malo C.Caco 2 cells cultured in serum-free medium as a model for the study of enterocytic dif-ferentiationin vitro[J].J Cell Physiol,1991,149(1):24-33.
• [21]沙先谊,方晓玲,吴云娟.9硝基喜树碱在Caco 2细胞模型中的体外摄取、转运及外排动力学[J].药学学报,2004,39(10):839-843.
• [22]Walgren R A,Karnaky K J,Lindenmayer G E,et al.Efflux of dietary flavoniod quercetin 4′--βglucosideacross human intestinal Caco 2 cell monolayers by api-cal multidrug resistance-associated protein-2[J].JPharmacol Exp Ther,2000,294(3):830-836.
• [23]Vaidyanathan J B,Walle T.Transport and metabolismof tea flavonoid(-)-epicathechin by the human intesti-nal cell line Caco 2[J].Pharm Res,2001,18(10):1420-1425.
• [24]Perloff M D,Stormer E,von Moltke L L,et al.rapidassessment of P-glycoprotein inhibition and inductionin vitro[J].Pharm Res,2003,20(8):1177-1183.
• [25]Gan L L,Dhiren R T.Application of Caco 2 model inthe design and development of orally active drugs:elu-cidation of biochemical and physical barriers posed bythe intestinal epithelium[J].Adv Drug Deliv Rev,1997,23(1-3):77-98.
• [26]Tamai I.Molecular characterization of intestinal ab-sorption of drugs by carrier-mediated transport mecha-nisms[J].Yakugaku Zasshi,1997,117(7):415-434.
• [27]Westphal K,Weinbrenner A,Zschiesche M,et al.In-duction of P-glycoprotein by rifampin increases intesti-nal secretion of talinolol in human beings:A new typeof drug/drug interaction[J].Clin Pharmacol Ther,2000,68(4):345-355.
• [28]Hiroshi S,Yuichi S.Role of metabolic enzymes and ef-flux transporters in the absorption of drugs from thesmall intestine[J].Eur J Pharm Sci,2000,12(1):3-12.
• [29]Hovggard L,Brordsted H,Buur A.Drug delivery stud-ies in Caco 2 monolayers,synthesis,hydrolysis andtransport ofO-cyclopropane carboxylic acid ester pro-drugs of various-βblocking agents[J].Pharm Res,1995,12(3):387-392.
• [30]Hillgren K M,Kato A,Borchardt R T.In vitrosys-tems for studing intestinal drug absorption[J].MedRes Rev,1995,15(2):83-109.
• [31]Meunier V,Bourrie M,Berger Y,et al.The human in-testinal epithelial cell line Caco 2:pharmacological andpharmacokinetic applications[J].Cell Biol Toxicol,1995,11(3-4):187-194.
• [32]Hidalgo I J,Raub T J,Borchardt R T.Characterizationof the human colon carcinoma cell line(Caco 2)as amodel system for intestinal epithelial permeability[J].Gastroenterology,1989,96(3):736-749.